Susquehanna Fundamental Investments’s CRISPR Therapeutics CRSP Stock Holding History

Susquehanna Fundamental Investments’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-60,527	Closed	-$2.06M	–	789
2025 Q1	$2.06M	Sell	60,527 -31,860	-34%	-$1.35M	0.03%	522
2024 Q4	$3.64M	Buy	+92,387	New	+$4.36M	0.05%	395
2024 Q2	–	Sell	-23,503	Closed	-$1.6M	–	946
2024 Q1	$1.6M	Buy	+23,503	New	+$1.68M	0.07%	269
2022 Q4	–	Sell	-19,674	Closed	-$1.29M	–	1252
2022 Q3	$1.29M	Buy	+19,674	New	+$1.43M	0.02%	718
2022 Q1	$2M	Buy	31,932 +10,120	+46%	+$635K	0.04%	582
2021 Q4	$1.65M	Buy	21,812 +1,959	+10%	+$171K	0.04%	485
2021 Q3	$2.22M	Sell	19,853 -2,867	-13%	-$360K	0.04%	561
2021 Q2	$3.68M	Buy	+22,720	New	+$2.76M	0.07%	397

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna Fundamental Investments's CRSP Position: Q2 2025 in Review

Susquehanna Fundamental Investments sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 60,527 shares — an estimated $2.06M sold.

Susquehanna Fundamental Investments first reported a position in CRSP in Q2 2021 and held it in 8 quarters. The position peaked at $3.68M in Q2 2021. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

Susquehanna Fundamental Investments reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 60,527 CRISPR Therapeutics shares in Q2 2025, an estimated $2.06M.
Susquehanna Fundamental Investments first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 8 quarters.
Susquehanna Fundamental Investments's CRISPR Therapeutics position peaked at $3.68M in Q2 2021.
433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2025, filed 14 Aug 2025.